Cumberland Pharma

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Cumberland Pharma reports steady Q1 performance amidst sales challenges

Cumberland Pharma's Q1 2024 performance showcased resilience in the face of sales challenges, with a strategic emphasis on FDA-approved brands. The company's dedication to innovation and patient care underpins its growth trajectory, despite hurdles posed by insurance deductibles.

Cumberland Pharma reports revenue growth but faces profitability challenges

Cumberland Pharmaceuticals demonstrated revenue growth potential but grappled with profitability challenges in Q2 2024. The company's focus on innovation, market expansion, and patient care underscores a commitment to long-term success. Addressing cost management, profitability, and leveraging growth opportunities will be crucial for Cumberland's future.

Cumberland Pharma reports resilient Q3 performance amidst operational challenges

Cumberland Pharma's Q3 2024 performance was driven by FDA-approved brands despite challenges.
The company showcased improved financials with a focus on operational efficiency and growth opportunities.
While facing challenges like product returns and expenses, Cumberland maintains a strong financial position.
Strategic initiatives and research efforts position Cumberland for future growth and profitability.

Cumberland Pharma reports strong Q4 performance amidst profitability challenges

Cumberland Pharma's Q4 2024 performance reflects revenue growth and notable achievements in product development and regulatory milestones. While facing profitability challenges and market competition, the company's strong financial position and strategic focus on innovation position it well for future growth. Opportunities lie in expanding product applications, pursuing international partnerships, and leveraging acquisitions to drive revenue and market expansion.

Cumberland Pharma excels in Q1 2025, eyes growth in China

Cumberland Pharma's Q1 2025 performance reflects strong revenue growth, profitability, and strategic advancements. The company's financial stability, leadership focus, and pipeline progress position it well for future success. While facing industry challenges and financial considerations, Cumberland Pharma has opportunities for expansion and innovation.

Cumberland Pharma reports solid Q2 growth and eyes global expansion

Cumberland Pharma's Q2 2025 performance reflects steady revenue growth, a diverse product portfolio, and a strong financial position. The company's strengths lie in innovation, regulatory success, commitment to R&D, and a proactive approach to product development. Challenges include maintaining profitability, balancing R&D investments, market competition, and regulatory complexities. Opportunities for growth include exploring new markets, leveraging successful trials, strategic partnerships, and expanding the product pipeline.

Cumberland Pharma reports stable Q3 performance amidst growth opportunities

Cumberland Pharma's Q3 2025 performance reflects steady revenue growth and positive cash flow. Strengths lie in new product additions, international expansion, and progress in clinical programs. Challenges include managing costs, accelerating revenue growth, and navigating regulatory landscape. Opportunities exist in collaborations, international markets, medical advancements, and financial strengthening.

Cumberland Pharma (CPIX) reports strong earnings and growth opportunities

Cumberland Pharma's Q4 2025 earnings call highlighted robust financial performance, strategic brand acquisitions, and advancements in clinical programs. While facing challenges of rising expenses and market competition, the company's strong revenue growth and innovative pipeline position it well for future success. Opportunities in global expansion, clinical research, and strategic partnerships offer avenues for sustained growth and market leadership in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.